Skip to main content

Advertisement

SpringerLink
Log in

Fertility preservation for female cancer patients

  • Invited Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

An improvement in the survival rates of cancer patients and recent advancements in assisted reproductive technologies have led to remarkable progress in oncofertility and fertility preservation treatments. Currently, for adults and postpubertal girls, oocyte or embryo cryopreservation is an established method. If their cancer treatment cannot be postponed for 2 weeks, ovarian tissue cryopreservation is offered as an experimental technique. For prepubertal girls, ovarian tissue cryopreservation is the only option. As for ovarian protection, there is insufficient evidence regarding the effectiveness of GnRH agonist in fertility preservation. In the past decade, the concept of fertility preservation for cancer patients has been rapidly spreading, but at present only a small part of young cancer patients receive fertility preservation services. It is partly because of the lack of adequate provision of information on fertility preservation and the lack of referral from oncology to the fertility clinic. In Japan, the clinical practice guidelines for fertility preservation in childhood, adolescent and young adult cancer patients was issued last year by the Japan Society of Clinical Oncology (JSCO). It would help Japanese health care providers, including oncologists and reproductive specialists, to increase their knowledge on fertility preservation for cancer patients and move forward the fertility preservation services. For further progress, it is also needed to establish a national registration system of fertility preservation for cancer patients to evaluate the safety and efficacy of the current management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Phillips SM, Padgett LS, Leisenring WM et al (2015) Survivors of childhood cancer in the United States: prevalence and burden of morbidity. Cancer Epidemiol Prev Biomark 24:653–663

    Article  Google Scholar 

  2. Martinez F (2017) Update on fertility preservation from the Barcelona International Society for Fertility Preservation–ESHRE–ASRM 2015 expert meeting: indications, results and future perspectives. Fertil Steril 108(407–415):e411

    Google Scholar 

  3. Donnez J, Dolmans MM (2017) Fertility preservation in women. N Engl J Med 377:1657–1665

    Article  PubMed  Google Scholar 

  4. Loren AW, Mangu PB, Beck LN et al (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:2500–2510

    Article  PubMed  PubMed Central  Google Scholar 

  5. Cobo A, Garcia-Velasco JA, Coello A et al (2016) Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril 105(755–764):e758

    Google Scholar 

  6. Oktay K, Turan V, Bedoschi G et al (2015) Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol 33:2424–2429

    Article  PubMed  PubMed Central  Google Scholar 

  7. Harada M, Osuga Y (2016) Where are oncofertility and fertility preservation treatments heading in 2016? Future Oncol 12:2313–2321

    Article  CAS  PubMed  Google Scholar 

  8. Dolmans MM (2018) Recent advances in fertility preservation and counseling for female cancer patients. Expert Rev Anticancer Ther 18:115–120

    Article  CAS  PubMed  Google Scholar 

  9. Rienzi L, Gracia C, Maggiulli R et al (2017) Oocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance. Hum Reprod Update 23:139–155

    CAS  PubMed  Google Scholar 

  10. von Wolff M, Montag M, Dittrich R et al (2011) Fertility preservation in women—a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet 284:427–435

    Article  Google Scholar 

  11. Cakmak H, Rosen MP (2013) Ovarian stimulation in cancer patients. Fertil Steril 99:1476–1484

    Article  PubMed  Google Scholar 

  12. Reddy J, Turan V, Bedoschi G et al (2014) Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J Assist Reprod Genet 31:927–932

    Article  PubMed  PubMed Central  Google Scholar 

  13. Reddy J, Oktay K (2012) Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertil Steril 98:1363–1369

    Article  CAS  PubMed  Google Scholar 

  14. Kim J, Turan V, Oktay K (2016) Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab 101:1364–1371

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Cakmak H, Katz A, Cedars MI et al (2013) Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril 100:1673–1680

    Article  PubMed  Google Scholar 

  16. Grynberg M, Poulain M, le Parco S et al (2016) Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients. Hum Reprod 31:623–629

    Article  CAS  PubMed  Google Scholar 

  17. Boots CE, Meister M, Cooper AR et al (2016) Ovarian stimulation in the luteal phase: systematic review and meta-analysis. J Assist Reprod Genet 33:971–980

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ubaldi FM, Capalbo A, Vaiarelli A et al (2016) Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril 105:1488–1495

    Article  PubMed  Google Scholar 

  19. Vaiarelli A, Venturella R, Vizziello D et al (2017) Dual ovarian stimulation and random start in assisted reproductive technologies: from ovarian biology to clinical application. Curr Opin Obstet Gynecol 29:153–159

    Article  PubMed  Google Scholar 

  20. Practice Committees of American Society for Reproductive Medicine; Society for Assisted Reproductive Technology (2013) Mature oocyte cryopreservation: a guideline. Fertil Steril 99:37–43

    Article  Google Scholar 

  21. Practice Committee of American Society for Reproductive Medicine (2014) Ovarian tissue cryopreservation: a committee opinion. Fertil Steril 101:1237–1243

    Article  Google Scholar 

  22. Dolmans MM, Marotta ML, Pirard C et al (2014) Ovarian tissue cryopreservation followed by controlled ovarian stimulation and pick-up of mature oocytes does not impair the number or quality of retrieved oocytes. J Ovarian Res 7:80

    Article  PubMed  PubMed Central  Google Scholar 

  23. Donnez J, Dolmans MM, Diaz C et al (2015) Ovarian cortex transplantation: time to move on from experimental studies to open clinical application. Fertil Steril 104:1097–1098

    Article  PubMed  Google Scholar 

  24. Donnez J, Dolmans MM (2015) Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice. J Assist Reprod Genet 32:1167–1170

    Article  PubMed  PubMed Central  Google Scholar 

  25. Stoop D, Cobo A, Silber S (2014) Fertility preservation for age-related fertility decline. Lancet 384:1311–1319

    Article  PubMed  Google Scholar 

  26. Van der Ven H, Liebenthron J, Beckmann M et al (2016) Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates. Hum Reprod 31:2031–2041

    Article  PubMed  Google Scholar 

  27. Meirow D, Ra’anani H, Shapira M et al (2016) Transplantations of frozen-thawed ovarian tissue demonstrate high reproductive performance and the need to revise restrictive criteria. Fertil Steril 106:467–474

    Article  PubMed  Google Scholar 

  28. Jensen AK, Macklon KT, Fedder J et al (2017) 86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children. J Assist Reprod Genet 34:325–336

    Article  PubMed  Google Scholar 

  29. Bastings L, Beerendonk CC, Westphal JR et al (2013) Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Hum Reprod Update 19:483–506

    Article  CAS  PubMed  Google Scholar 

  30. Dolmans MM, Luyckx V, Donnez J et al (2013) Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertil Steril 99:1514–1522

    Article  PubMed  Google Scholar 

  31. Rosendahl M, Greve T, Andersen CY (2013) The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. J Assist Reprod Genet 30:11–24

    Article  PubMed  Google Scholar 

  32. Moore HC, Unger JM, Phillips KA et al (2015) Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 372:923–932

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Roberts J, Ronn R, Tallon N et al (2015) Fertility preservation in reproductive-age women facing gonadotoxic treatments. Curr Oncol 22:e294–e304

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Lambertini M, Boni L, Michelotti A et al (2015) Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA 314:2632–2640

    Article  CAS  PubMed  Google Scholar 

  35. Demeestere I, Brice P, Peccatori FA et al (2016) No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol 34:2568–2574

    Article  CAS  PubMed  Google Scholar 

  36. Kim SS, Donnez J, Barri P et al (2012) Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J Assist Reprod Genet 29:465–468

    Article  PubMed  PubMed Central  Google Scholar 

  37. Yee S (2016) Factors associated with the receipt of fertility preservation services along the decision-making pathway in young Canadian female cancer patients. J Assist Reprod Genet 33:265–280

    Article  PubMed  Google Scholar 

  38. Jones G, Hughes J, Mahmoodi N et al (2017) What factors hinder the decision-making process for women with cancer and contemplating fertility preservation treatment? Hum Reprod Update 23:433–457

    Article  PubMed  Google Scholar 

  39. Partridge AH, Gelber S, Peppercorn J et al (2004) Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 22:4174–4183

    Article  PubMed  Google Scholar 

  40. Tschudin S, Bunting L, Abraham J et al (2010) Correlates of fertility issues in an internet survey of cancer survivors. J Psychosom Obstet Gynaecol 31:150–157

    Article  PubMed  Google Scholar 

  41. Shimizu C, Bando H, Kato T et al (2013) Physicians’ knowledge, attitude, and behavior regarding fertility issues for young breast cancer patients: a national survey for breast care specialists. Breast Cancer 20:230–240

    Article  PubMed  Google Scholar 

  42. Quinn GP, Vadaparampil ST, King L et al (2009) Impact of physicians’ personal discomfort and patient prognosis on discussion of fertility preservation with young cancer patients. Patient Educ Couns 77:338–343

    Article  PubMed  Google Scholar 

  43. Shea LD, Woodruff TK, Shikanov A (2014) Bioengineering the ovarian follicle microenvironment. Annu Rev Biomed Eng 16:29–52

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Hikabe O, Hamazaki N, Nagamatsu G et al (2016) Reconstitution in vitro of the entire cycle of the mouse female germ line. Nature 539:299–303

    Article  CAS  PubMed  Google Scholar 

  45. Roness H, Kashi O, Meirow D (2016) Prevention of chemotherapy-induced ovarian damage. Fertil Steril 105:20–29

    Article  CAS  PubMed  Google Scholar 

  46. Li F, Turan V, Lierman S et al (2014) Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death. Hum Reprod 29:107–113

    Article  CAS  PubMed  Google Scholar 

  47. Gonfloni S, Di Tella L, Caldarola S et al (2009) Inhibition of the c-Abl–TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med 15:1179–1185

    Article  CAS  PubMed  Google Scholar 

  48. Kalich-Philosoph L, Roness H, Carmely A et al (2013) Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility. Sci Transl Med 5:185ra162

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by Grants from the Ministry of Health, Labor and Welfare and from the Japan Agency for Medical Research and Development (AMED) (to Y.O.).

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Miyuki Harada & Yutaka Osuga

Authors
  1. Miyuki Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yutaka Osuga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yutaka Osuga.

Ethics declarations

Conflict of interest

The authors declare no potential conflicts of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harada, M., Osuga, Y. Fertility preservation for female cancer patients. Int J Clin Oncol 24, 28–33 (2019). https://doi.org/10.1007/s10147-018-1252-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-018-1252-0

Keywords

Search

Navigation